Loading
Ipsen SA Stock: price and insider trades · France
2 insiders bought €154k of shares over the last 90 days, the latest filed 22 Sept 2026.
Ipsen SA: what insiders have been doing
Ipsen SA, founded in 1929, is a Healthcare & Pharma company based in France. Its latest reported headcount is 5,300 employees (2024). Its directors and officers file their transactions with AMF. 5 insiders have disclosed 12 filings since 18 October 2025.
On the market, 2 insiders bought (2 purchases totalling €154k) while 3 insiders sold (9 sales totalling €7.6M). On balance, insiders were net sellers of €7.5M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The buyers include 2 board members. Biggest ticket of the year: €2.3M, sold by David LOEW and made public on 10 August 2026 (0.019% of market cap).
For context, the typical company on the same exchange (median of 316 companies) published 6 filings over the same period, against 12 filings here. Looking back to 2021, when coverage begins, insiders filed 3 purchases and 20 sales.
In all, 1 purchase was made within 30 days of a purchase by another insider of the company. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The clock since the last published purchase (22 September 2026) now reads 25 days. Between a trade and the moment it shows up on AMF, the median delay is 1 day. The regulation allows three business days to notify a trade (MAR article 19). Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Cytosorbents Corp. Source: insider filings from AMF. Past trades are no guide to future returns.
Insider Decl.
29
Thresholds
n/a
Buy Volume
€205,466
3 ops. · all time
Sell Volume
€11M
20 ops. · all time
Who traded when
BuySaleDavid LOEW14 sales
Catherine BRADLEY1 buy
Laetitia Ducroquet1 sale
Marc de Garidel Thoron1 sale
Marc DE GARIDEL-THORON1 sale
Peter GUENTER1 buy
Since the insiders bought
- -9.2%Entry €157.10 · Close 13 Oct 2026 €142.60
- +10.8%Entry €101.50 · Close at T+365 €112.50
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Ipsen SA Hold (neutral), based on 14 analysts. Average price target: €164.29.
Fundamental score
Ranked 4,146 of 24,158 companies
68.5
score / 100
Value61
Quality76
FCF yld6.6%
Earn yld3.6%
EV/EBITDA10.5x
ROE11%
Gross mgn81%
Net mgn11%
Debt/EBITDA0.7x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
€145.60
Analyst consensus
14 analystsHold
€130.00Target €164.29(+13%)€235.00
Income statement
Revenue€3.9B
Gross profit€3.2B81% margin
EBITDA€1.2B32% margin
Net income€443.5M11.9% margin
Valuation
PER (trailing)23.6x
PER (forward)10.4x
P/Book2.5x
Beta0.35
Balance sheet & cash
Market cap€12.0B
Total debt€867.1M
Free Cash Flow€809.7M
Debt / Equity20%
Profitability & ownership
ROE11.4%
ROA10.3%
% insiders57.6%
% institutions21.7%
Last declaration on 22 September 2026
Declarations29 total
500 shares@ €147.200.0006% mcap100.0% of flowActionEuronext ParisISIN FR00102591502026DD1139474
Canonical exit: 20 Dec 2026 (T+90)
500 shares@ €159.900.0007% mcap100.0% of flowActionEuronext ParisISIN FR00102591502026DD1137249
Canonical exit: 7 Dec 2026 (T+90)
1,000 shares@ €170.000.0014% mcap65.0% of flowActionEuronext ParisISIN FR00102591502026DD1136456
3,840 shares@ €161.58540.0051% mcap100.0% of flowActionEuronext ParisISIN FR00102591502026DD1134753
1,000 shares@ €163.000.0013% mcap1.7% of flowActionEuronext ParisISIN FR00102591502026DD1134158
8,000 shares@ €161.550.011% mcap13.3% of flowActionEuronext ParisISIN FR00102591502026DD1133908
14,300 shares@ €162.64990.019% mcap23.9% of flowActionEuronext ParisISIN FR00102591502026DD1132860
8,900 shares@ €162.42580.012% mcap14.9% of flowActionEuronext ParisISIN FR00102591502026DD1132626
5,000 shares@ €169.63660.0069% mcap8.7% of flowActionEuronext ParisISIN FR00102591502026DD1131435
26,583 shares0ActionHors plateforme de négociationISIN FR00102591502026DD1117831
1,000 shares@ €160.05230.0012% mcap100.0% of flowActionEuronext ParisISIN FR00102591502026DD1117300
3,800 shares@ €158.200.0044% mcap100.0% of flowActionEuronext ParisISIN FR00102591502026DD1096507
28,008 shares0ActionHors plateforme de négociationISIN FR00102591502025DD1040027
1,500 shares@ €112.87561.7% of flowActionEuronext ParisISIN FR00102591502025DD1025484
2,000 shares@ €111.8752.3% of flowActionEuronext ParisISIN FR00102591502025DD1024363
2,000 shares@ €114.402.4% of flowActionEuronext ParisISIN FR00102591502025DD1023989
2,000 shares@ €112.90122.3% of flowActionEuronext ParisISIN FR00102591502025DD1023567
2,000 shares@ €111.68942.3% of flowActionEuronext ParisISIN FR00102591502025DD1023315
2,000 shares@ €113.11252.3% of flowActionEuronext ParisISIN FR00102591502025DD1023336
2,000 shares@ €110.502.3% of flowActionEuronext ParisISIN FR00102591502025DD1022995
2,000 shares@ €111.78012.3% of flowActionEuronext ParisISIN FR00102591502025DD1022187
850 shares@ €107.499635.0% of flowActionEuronext ParisISIN FR00102591502024DD993950
7,800 shares@ €121.80069.8% of flowActionEuronext ParisISIN FR00102591502024DD969297
39,984 shares0ActionHors plateforme de négociationISIN FR00102591502024DD968037
7,800 shares@ €122.17539.8% of flowActionEuronext ParisISIN FR00102591502024DD967353
25 of 29 declarations
About Ipsen SA
Ipsen SA is a French biopharmaceutical group listed in Paris under ISIN FR0010259150. The company develops and markets specialty medicines focused on three core therapeutic areas: oncology, rare disease, and neuroscience. Ipsen is positioned as a niche, science-driven healthcare company that relies on external innovation, clinical development, and global partnerships to expand its portfolio. In its most recent public communications, the group states that its medicines are available in more than 80 countries and that it operates through teams in more than 40 countries, supported by major hubs in France, the United States, and the United Kingdom.
Ipsen’s roots go back nearly a century, and the company has evolved from a French industrial base into an international specialty biopharma business. Over time, it has built a reputation around prescription medicines addressing highly targeted medical needs rather than mass-market products. That strategic positioning has been reinforced by sustained investment in research and development, a strong emphasis on licensing and partnerships, and selective business development to add differentiated assets to the pipeline.
Read moreShow less
The company’s product portfolio spans several well-known specialty medicines and development programs. Ipsen highlights a broad platform in oncology, rare diseases, and neuroscience, with a business model centered on specialty products that can generate durable value through lifecycle management, label expansion, and regulatory milestones. Recent corporate updates indicate continued momentum across the pipeline, supported by product launches, clinical progress, and approvals that help refresh the growth profile of the group.
Geographically, Ipsen is truly global. Although headquartered in France, the group derives a substantial portion of its activity outside its home market through a worldwide commercial organization and partnerships that extend its reach. Ipsen says it has products registered in more than 80 countries and around 5,000 employees worldwide, underlining its scale as a mid-sized but internationally relevant pharmaceutical company. The company also regularly publishes its Universal Registration Document and annual reports, reflecting a structured governance framework and a disciplined approach to investor communication.
A notable recent development is Ipsen’s continued expansion through external innovation and regulatory execution. In April 2026, the company announced a conditional marketing authorization in Europe for Ojemda® in a rare pediatric indication, illustrating its ability to convert research and partnerships into commercial opportunities. Overall, Ipsen stands out as a specialized French healthcare group combining therapeutic focus, global reach, and a steady pipeline-led growth strategy.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
